TY  - GEN
AU  - Moore,Kathleen N
AU  - Borghaei,Hossein
AU  - O'Malley,David M
AU  - Jeong,Woondong
AU  - Seward,Shelly M
AU  - Bauer,Todd M
AU  - Perez,Raymond P
AU  - Matulonis,Ursula A
AU  - Running,Kelli L
AU  - Zhang,Xiaoyan
AU  - Ponte,Jose F
AU  - Ruiz-Soto,Rodrigo
AU  - Birrer,Michael J
TI  - Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors
SN  - 1097-0142
PY  - 2017///0911
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antibodies, Monoclonal, Humanized
KW  - therapeutic use
KW  - Antineoplastic Agents
KW  - Carcinoma, Non-Small-Cell Lung
KW  - drug therapy
KW  - Carcinoma, Ovarian Epithelial
KW  - Carcinoma, Renal Cell
KW  - Diarrhea
KW  - chemically induced
KW  - Disease Progression
KW  - Dose-Response Relationship, Drug
KW  - Endometrial Neoplasms
KW  - Fatigue
KW  - Female
KW  - Humans
KW  - Hypophosphatemia
KW  - Immunoconjugates
KW  - Keratitis
KW  - Kidney Neoplasms
KW  - Lung Neoplasms
KW  - Male
KW  - Maximum Tolerated Dose
KW  - Maytansine
KW  - analogs & derivatives
KW  - Middle Aged
KW  - Neoplasms
KW  - Neoplasms, Glandular and Epithelial
KW  - Ovarian Neoplasms
KW  - Vision Disorders
N1  - Publication Type: Clinical Trial, Phase I; Journal Article
UR  - https://doi.org/10.1002/cncr.30736
ER  -